论文部分内容阅读
目的:分析孟鲁司特联合沙美特罗替卡松治疗支气管哮喘临床效果。方法:以我院从2012年8月到2015年2月收治的80名支气管哮喘患者为例,将患者平均分为实验组和对照组,前者口服孟鲁斯特10mg,1次/d,吸入沙美特罗替卡松50μg/250μg,1次/d,对照组仅采用吸入沙美特罗替卡松50μg/250μg,1次/d,观察两组患者在ACT、PEF及不良反应上的差异。结果:两组患者在ACT评分及PEF测试上与治疗前相比都有明显的差异(P>0.0),两组患者治疗后在ACT评分及PEF测试上差异不具有统计学意义(P<0.05),两组患者在治疗期间均未出现不良反应。结论:口服孟鲁司特联合沙美特罗替卡松治疗,可以减轻吸入治疗的痛苦,具有安全有效、副作用小的优势。
Objective: To analyze the clinical effect of montelukast combined with salmeterol and fluticasone in the treatment of bronchial asthma. Methods: A total of 80 patients with bronchial asthma admitted from August 2012 to February 2015 in our hospital were divided equally into experimental group and control group. The former received oral administration of montelukast 10 mg once daily and inhaled Salmeterol and Tacrolimus 50μg / 250μg, 1 times / d, the control group only inhaled salmeterol / tacrolimus 50μg / 250μg, 1 / d, the two groups of patients in ACT, PEF and adverse reactions differences. Results: There was a significant difference between the two groups in ACT score and PEF test before treatment (P> 0.05). There was no significant difference in ACT score and PEF between the two groups after treatment (P <0.05 ), Two groups of patients during the treatment did not appear adverse reactions. Conclusion: Oral montelukast combined with salmeterol / tacoceptor can reduce the pain of inhalation therapy, which is safe, effective and has few side effects.